Expression of HMGB1 in clinical samples was first reported by Kuniyasu et al. [21] in a pilot study where they found that HMGB1 is expressed in tumor (27%) and stromal cells (63%) of metastatic patients. This evidence concerns the gene HMGB1 and neoplasm.